Oncología

Resultados: 451
Tipo Título / Nombre Autor(es) Año
Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study García Campelo MR, Dómine M, Castro Carpeño J de. Moreno Vega AL..., Alonso Calderón R 2023
Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, realworld evidence in Spain (GEM 2002 - BECARE) Soria A, Sánchez Mauriño P, García Galindo R..., Ayala de Miguel P 2023
Tolerability and effectiveness of niraparib in long-term responders with platinum-sensitive recurrent ovarian cancer (GEICO-88R study) Cueva Banuelos JF, Salvador Coloma C, Gálvez Montosa F..., González Santiago S 2023
PROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Efficacy results from the pilot phase Arranz Arija JA, Piulats Rodríguez JM, Vázquez Estévez S..., Martín RC 2023
Coping strategies as mediators of uncertainty and psychological distress in patients with advanced cancer Obispo B, Cruz-Castellanos P, Fernández-Montes A, Coca-Membribes S, Rogado J..., López-Ceballos H, et al 2023
The Role of Financial Difficulties as a Mediator between Physical Symptoms and Depression in Advanced Cancer Patients Lee EM, Jiménez-Fonseca P, Hernández R, Cruz-Castellanos P, Fernández-Montes A..., López-Ceballos H, et al 2023
What do patients and oncologists think about the evaluation and management of cancer?related anorexia?cachexia? The Quasar_ SEOM study Escobar Y, Ramchandani A, Castillo-Trujillo A, Martínez de Castro E..., Borrega P 2023
ATREZZO trial (SOLTI-1907): A phase II trial targeting estrogen receptor negative or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive (HER2+) advanced breast cancer (ABC) - Interim analysis Ciruelos EM, Tolosa Ortega P, Salvador Bofill FJ, González Santiago S, Albacar Miro CR 2023
Time and motion randomised study of a subcutaneous (SC) pertuzumab and trastuzumab fixed-dose combination (PH FDC) for the treatment of HER2-positive early breast cancer (HER2 EBC): PHaTiMa González Santiago S, López Miranda E, Escrivá Romani S, Jiménez Rodríguez B, Antolin Novoa S, González Cortijo L, et al 2023
Infección fúngica en paciente oncológico Espacio Santos PM 2023